Evidence map›Paper›PMID 37363504›Full record

ArticleAnnals of medicine and surgery (2012)2023

Analysis of natural resistance-associated macrophage protein-1 (NRAMP-1) level based on death, comorbidities and severity of COVID-19 patients: a cross-sectional study.

Ressy Dwiyanti, Annisa Anwar Muthaher, Djumadi Achmad, Gunawan Arsyadi, Berti J Nelwan, Muhammad Husni Cangara, Gatot S Lawrence, Cahyono Kaelan, Jerny Dase, Denny Mathius and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Ressy DwiyantiDepartments ofForensic and Medicolegal.
Annisa Anwar MuthaherDepartments ofForensic and Medicolegal.
Djumadi AchmadDepartments ofForensic and Medicolegal.
Gunawan ArsyadiDepartments ofForensic and Medicolegal.
Berti J NelwanDepartments ofForensic and Medicolegal.
Muhammad Husni CangaraDepartments ofForensic and Medicolegal.
Gatot S LawrenceDepartments ofForensic and Medicolegal.
Cahyono KaelanDepartments ofForensic and Medicolegal.
Jerny DaseDepartments ofForensic and Medicolegal.
Denny MathiusDepartments ofForensic and Medicolegal.
A R IndrayatyDepartments ofForensic and Medicolegal.
Afriani EarlyDepartments ofForensic and Medicolegal.
Ade Rifka JunitaPost Graduate School.ORCID 0000-0002-6257-3061
Andini FebriantiDepartments ofForensic and Medicolegal.
Eva Sri DianaPost Graduate School.
Muhammad FachriDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia.
Ahmad SyukriPost Graduate School.ORCID 0000-0003-3873-9313
Muhammad Reza PrimagunaInternal Medicine.
Azhar AzharPulmonology and Respiratory Medicine, Faculty of Medicine.
Mochammad HattaPost Graduate School.ORCID 0000-0002-8456-4203
Medico · CZHasanuddin University · IDTadulako University · IDUniversitas Muhammadiyah Jakarta · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An accurate diagnosis of COVID-19 is essential for pandemic control and for establishing adequate therapeutic strategies to reduce morbidity and mortality. COVID-19 infection replicates in macrophage cells and affects the immune system. Natural resistance-associated macrophage protein-1 (NRAMP-1) carries cation ions, such as Fe2+, Zn2+ and Mn2+, and plays an essential role in the immune system to infection with micro-organisms. In addition, the function of NRAMP-1 is to limit the replication of pathogens by changing the phagosomal environment. Levels of NRAMP-1 protein are based on death, comorbidities and clinical symptoms of COVID-19 patients and it is possible for the soluble protein NRAMP-1 level to be used as an additional biomarker for forensic and medicolegal related COVID-19 cases and prosecutions from patients and families. Methods: Determination of NRAMP-1 protein levels using the enzyme link-immunosorbent assay technique in death, had comorbidities and severity of clinical symptoms of COVID-19 patients. Results: Of the 62 patients who received treatment, 10 patients died with an average NRAMP-1 level of 650 ng/ml and 52 patients who survive with an average NRAMP-1 level of 1065.26 ng/ml. The results of the study also found that 34 patients had comorbidities with an average NRAMP-1 level of 838.82 ng/ml and 28 patients without comorbidities with an average NRAMP-1 level of 1191.92 ng/ml. Based on the severity of clinical symptoms in survive patients, 10 patients with mild were found with an average NRAMP-1 level of 984.31 ng/ml, with moderate in 31 patients with an average NRAMP-1 level of 1104.71 ng/ml and severe in 11 patients with an average NRAMP-1 level of 1027.71 ng/ml. Conclusions: NRAMP-1 protein levels were significantly lower in COVID-19 patients who died and had comorbidities.

Indexed as

ComorbiditiesCOVID-19deathELISANRAMP-1severity

Identifiers

PMID37363504
PMCPMC10289594
OpenAlexW4382182186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.